Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tango Therapeutics (TNGX) Shares Issued (2020 - 2024)

Tango Therapeutics has reported Shares Issued over the past 5 years, most recently at $41.7 million for Q1 2024.

  • Quarterly results put Shares Issued at $41.7 million for Q1 2024, up 57054.79% from a year ago — trailing twelve months through Sep 2024 was $41.8 million (changed N/A YoY), and the annual figure for FY2023 was $689000.0, changed.
  • Shares Issued for Q1 2024 was $41.7 million at Tango Therapeutics, up from $73000.0 in the prior quarter.
  • Over the last five years, Shares Issued for TNGX hit a ceiling of $166.8 million in Q4 2020 and a floor of $25000.0 in Q2 2020.
  • Median Shares Issued over the past 5 years was $352000.0 (2021), compared with a mean of $26.8 million.
  • Biggest five-year swings in Shares Issued: plummeted 99.94% in 2021 and later skyrocketed 57054.79% in 2024.
  • Tango Therapeutics' Shares Issued stood at $166.8 million in 2020, then plummeted by 99.94% to $101000.0 in 2021, then surged by 162.38% to $265000.0 in 2022, then plummeted by 72.45% to $73000.0 in 2023, then skyrocketed by 57054.79% to $41.7 million in 2024.
  • The last three reported values for Shares Issued were $41.7 million (Q1 2024), $73000.0 (Q1 2023), and $265000.0 (Q1 2022) per Business Quant data.